Fig. 1: Tumor pathologic features and nTIL density. | Signal Transduction and Targeted Therapy

Fig. 1: Tumor pathologic features and nTIL density.

From: CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients

Fig. 1

a Clinical profile of patients included in the study. Database lock: December 12, 2024; minimum follow-up: 12 months; median follow-up: 25 months. b Representative images showing the immunohistochemical staining of CD3 and CD8 in regions of tumor necrosis in samples from two NSCLC patients. Scale bars, 200 μm. c Pathologic features (percentage of RVT, regression and necrosis) in patients with tumor necrosis (n = 99). d CD3+ nTIL and CD8+ nTIL density in patients listed in (c). e Tumor PD-L1 status, LN metastasis, pathological response and outcome in patients listed in A. “LN metastasis after therapy” was confirmed through pathological diagnosis of the surgical samples following neoadjuvant therapy. f and g. CD3+ (f) and CD8+ (g) nTIL density for each patient in the MPR (n = 53) and non-MPR (n = 46) groups (left), and pie charts show the proportion of patients with high or low nTIL density in the MPR and non-MPR groups (right)

Back to article page